ArticleScientific reports2026
Berberine-entrapped albumin nanoparticles ameliorate chemically induced liver injury by restoring oxidative balance and autophagic-apoptotic crosstalk.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated the therapeutic potential of berberine-entrapped bovine serum albumin nanoparticles (BRB-BSA NPs) in alleviating chemically induced liver injury in rats. Molecular docking was first performed to examine BRB interactions with phosphoinositide 3-kinase (PI3K), a key regulator of cellular survival and autophagy pathways. Hepatotoxicity was induced using diethylnitrosamine (DEN) and carbon tetrachloride (CCl₄), resulting in significantly elevated serum uric acid levels (1.35 ± 0.1 mg/dL), oxidative imbalance, disrupted autophagic signaling, and histological liver damage. Post-injury treatment with BRB-BSA NPs significantly reduced serum uric acid (0.20 ± 0.07 mg/dL, p < 0.05 vs. DEN/CCl4), surpassing the prophylactic regimen and restoring levels comparable to healthy controls. Oxidative status improved, with increased superoxide dismutase (SOD) activity and reduced nitric oxide (NO) and xanthine oxidase (XO) levels. Autophagic signaling was normalized through downregulation of PI3K, mTOR, and p62, alongside upregulation of LC3, indicating restoration of autophagic flux. Apoptotic balance shifted toward pro-apoptotic signaling, with elevated Bax and reduced Bcl-2 expression, supporting the therapeutic potential that BRB-BSA NPs may exert. Histological assessment confirmed near-complete hepatic architecture recovery in the treatment group, while the prophylactic group exhibited partial protection. Collectively, these findings highlight the potent therapeutic role of BRB-BSA NPs in reversing DEN/CCl4− induced hepatic damage by restoring metabolic, oxidative, autophagic, and apoptotic homeostasis, underscoring their promise as a nanoformulated hepatoprotective intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.